Cell Therapy News/Articles, page-17640

Hi @LearningEachDay,

Yep, this is SPI and I'd like to hear more about the neurogenesis being talked about in this quote:

" Currently, there is a substantial body of evidence generated from preclinical studies indicating MSCs may potentially modulate various pathways involved in endogenous neurogenesis, angiogenesis, immunological regulation, and neuronal plasticity. Compared with other adult stem cells, AD-MSCs are particularly advantageous, given their angiogenic and neuro-regenerative capacity, in addition to their pluripotency, ease of harvest, and availability"

but 'angiogenesis' sounds a lot like the stimulation of neovascularization to me, & I know a MSC product that just showed the whole of Boston what that might look like in a Phase III trial in kids.

What's more there's already good research work on BM-MSCs in neurogenesis, which is exciting: e.g.this article. Is there a role in the SPI indication for Rexlemestrocel? Maybe. And, despite the authors' obvious preference for AD-MSCs, I would have thought a surgeon may well prefer to work in clinic with an approved allogeneic product, despite cost savings, if only due to the facts that the source donor won't have been immuno-compromised, and the allogeneic product had to jump such high safety and standardization hurdles to get there.

Anyway, I think you're absolutely right to note that clinical paradigms are shifting to cellular therapies across the board - even in a disorder as sensitive as SPI.

Cheers